within Pharmacolibrary.Drugs.ATC.L;

model L04AA19
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.06666666666666667,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Gusperimus is an immunosuppressive agent, a derivative of the antineoplastic compound spergualin. It has been investigated for its potential use in organ transplantation and autoimmune diseases, particularly as an immunosuppressant to prevent transplant rejection and in conditions like Wegener's granulomatosis. However, gusperimus is not an approved drug in current clinical practice and is not widely used.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies with specific quantified data for gusperimus are available in the scientific literature. Therefore, pharmacokinetic parameters are estimated based on known properties of similar immunosuppressive agents and structure-related compounds; these are generic estimates and not empirically measured for gusperimus.</p><h4>References</h4><ol><li><p>Tamura, K, et al., &amp; Suzuoki, Y (1995). Phase I study of NKT-01. <i>Cancer chemotherapy and pharmacology</i> 36(3) 189–194. DOI:<a href=&quot;https://doi.org/10.1007/BF00685845&quot;>10.1007/BF00685845</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7781137/&quot;>https://pubmed.ncbi.nlm.nih.gov/7781137</a></p></li><li><p>Gruber, SA, et al., &amp; Singh, J (1997). Pharmacokinetics and pharmacodynamics of 15-deoxyspergualin in a canine renal allograft model of local immunosuppression. <i>The Journal of surgical research</i> 71(2) 137–144. DOI:<a href=&quot;https://doi.org/10.1006/jsre.1997.5156&quot;>10.1006/jsre.1997.5156</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9299281/&quot;>https://pubmed.ncbi.nlm.nih.gov/9299281</a></p></li><li><p>Ohlman, S, et al., &amp; Lindholm, A (1994). Pharmacokinetics of 15-deoxyspergualin studied in renal transplant patients receiving the drug during graft rejection. <i>Transplant international : official journal of the European Society for Organ Transplantation</i> 7(1) 5–10. DOI:<a href=&quot;https://doi.org/10.1007/BF00335656&quot;>10.1007/BF00335656</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8117404/&quot;>https://pubmed.ncbi.nlm.nih.gov/8117404</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AA19;
